Prognostic Score Proposed for Patients With Advanced Melanoma Treated With Ipilimumab

Source: Cancer Therapy Advisor, November 2015

Researchers propose a simple prognostic score for survival that consists of 3 risk groups in patients with advanced melanoma treated with ipilimumab using readily available clinical parameters, according to a study published in the European Journal of Cancer.

Although immunotherapies like ipilimumab, a cytotoxic T-lymphocyte antigen 4 inhibitor, demonstrate durable clinical benefit in patients with advanced melanoma, there are no reliable prognostic markers or risk scores in this era of immunotherapy.

For the study, researchers collected characteristics and outcomes on 134 patients with metastatic melanoma who received ipilimumab between 2011 and 2014 at a single institution.

Menu